Despite the use and emergence of many therapeutic approaches for the treatment of DKD such as renin–angiotensin system blockers (ACE inhibitors and angiotensin receptor blockers), mineralocorticoid receptor blockers and sodium–glucose cotransporter 2 (SGLT2) inhibitors, there is still no cure and many patients still progress to end-stage renal disease (ESRD) [5,6,7]. This evidence concerns the gene SLC5A2 and chronic kidney disease.